IL182149A0 - Sulfonamide compounds - Google Patents

Sulfonamide compounds

Info

Publication number
IL182149A0
IL182149A0 IL182149A IL18214907A IL182149A0 IL 182149 A0 IL182149 A0 IL 182149A0 IL 182149 A IL182149 A IL 182149A IL 18214907 A IL18214907 A IL 18214907A IL 182149 A0 IL182149 A0 IL 182149A0
Authority
IL
Israel
Prior art keywords
sulfonamide compounds
sulfonamide
compounds
Prior art date
Application number
IL182149A
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL182149A0 publication Critical patent/IL182149A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
IL182149A 2004-09-24 2007-03-22 Sulfonamide compounds IL182149A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61272004P 2004-09-24 2004-09-24
PCT/US2005/033692 WO2006036670A1 (en) 2004-09-24 2005-09-19 Sulfonamide compounds

Publications (1)

Publication Number Publication Date
IL182149A0 true IL182149A0 (en) 2007-07-24

Family

ID=35781432

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182149A IL182149A0 (en) 2004-09-24 2007-03-22 Sulfonamide compounds

Country Status (18)

Country Link
US (3) US7297816B2 (en)
EP (1) EP1797083A1 (en)
JP (1) JP2008514608A (en)
KR (1) KR20070057252A (en)
CN (1) CN101061116A (en)
AR (1) AR050953A1 (en)
AU (1) AU2005289887A1 (en)
BR (1) BRPI0516027A (en)
CA (1) CA2581426A1 (en)
CR (1) CR9080A (en)
EA (1) EA200700717A1 (en)
EC (1) ECSP077360A (en)
IL (1) IL182149A0 (en)
MX (1) MX2007003623A (en)
NO (1) NO20072092L (en)
PE (1) PE20060823A1 (en)
WO (1) WO2006036670A1 (en)
ZA (1) ZA200702452B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545030A (en) * 2003-08-08 2009-08-28 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino) -benzamide compounds as CCK2 modulators
BRPI0516027A (en) 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv sulfonamide compounds
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
IN2012DN02556A (en) 2009-10-07 2015-08-28 Karobio Ab
JP5890312B2 (en) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド Sulfone compounds used in the treatment of obesity
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
BR112013018771A2 (en) 2011-01-26 2019-09-17 Zafgen Inc tetrazole compounds and methods for making and using them
BR112013028534A2 (en) 2011-05-06 2016-09-06 Zafgen Inc partially saturated tricyclic compounds and methods for their production and use
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
MX343688B (en) 2011-05-06 2016-11-16 Zafgen Inc Tricyclic pyrazole sulfonamide compounds and methods of making and using same.
AR088320A1 (en) 2011-10-14 2014-05-28 Incyte Corp ISOINDOLINONE AND PIRROLOPIRIDINONE DERIVATIVES AS AKT INHIBITORS
MX2014008705A (en) 2012-01-18 2015-02-05 Zafgen Inc Tricyclic sulfone compounds and methods of making and using same.
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN104640442A (en) 2012-06-14 2015-05-20 巴斯夫欧洲公司 Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
KR20150079952A (en) 2012-11-05 2015-07-08 자프겐 인크. Tricyclic compounds and methods of making and using same
CA2890344A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
BR112015010196A2 (en) 2012-11-05 2017-07-11 Zafgen Inc methods of treating liver disease
CN103183623A (en) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof
PL3071206T3 (en) 2013-11-22 2022-01-17 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
EP3087069B1 (en) * 2013-12-23 2019-01-30 Norgine B.V. Compounds useful as ccr9 modulators
CA2938571C (en) 2014-02-03 2020-12-22 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
CN106132406B (en) 2014-02-03 2020-03-27 夸德里加生物科学公司 β -substituted gamma-amino acids and analogs as chemotherapeutic agents
TWI665178B (en) 2015-08-03 2019-07-11 夸德里加生物科學公司 Beta-substituted beta-amino acid and analogue as chemotherapeutic agent and application thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT77219B (en) 1982-08-24 1986-02-04 May & Baker Ltd PROCESS FOR THE PREPARATION OF BENZAMIDE DERIVATIVES
CA1340191C (en) * 1988-06-13 1998-12-15 Katsuhiro Imaki Derivatives of p-substituted phenyl ester of pivalic acid
CA2057324A1 (en) * 1990-12-18 1992-06-19 Lora Louise Fitch Benzamide and sulfonamide hypoglycemic agents
IL101514A (en) 1991-04-10 1996-01-31 Merck & Co Inc Benzodiazepinone derivatives and cholecystokinin antagonist pharmaceutical compositions containing them
FR2703995B1 (en) 1993-04-16 1995-07-21 Sanofi Elf 5-ACYLAMINO 1,2,4-THIADIAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
AU721081B2 (en) 1996-12-10 2000-06-22 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
EP1187531A4 (en) 1999-06-24 2003-05-28 Smithkline Beecham Corp Macrophage scavenger receptor antagonists
DE10121002A1 (en) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Use of anthranilic acid amides as a medicament for the treatment of arrhythmias and pharmaceutical preparations containing them
DE10121003A1 (en) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
DE10128331A1 (en) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh New 2-(heteroarylsulfonyl-amino)-benzamide derivatives, which are potassium ion channel blocking antiarrhythmic agents, useful for e.g. treating atrial fibrillation or flutter
AR039241A1 (en) 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
ITTO20020674A1 (en) 2002-07-26 2004-01-26 Rotta Research Lab ANTRANYLIC DERIVATIVES WITH ANTI-CHOLOCYTOKININ ACTIVITY (ANTI-CCK-1), PROCEDURE FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
CA2520546A1 (en) * 2003-03-28 2005-02-10 Janssen Pharmaceutica, N.V. Benzo[1,2,5]thiadiazole compounds
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
GB0312360D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 4-amino-2(5H)-furanones
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
US20050042283A1 (en) 2003-07-11 2005-02-24 University Of Massachusetts Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
NZ545030A (en) 2003-08-08 2009-08-28 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino) -benzamide compounds as CCK2 modulators
BRPI0516027A (en) 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv sulfonamide compounds

Also Published As

Publication number Publication date
EA200700717A1 (en) 2007-10-26
BRPI0516027A (en) 2008-08-19
CA2581426A1 (en) 2006-04-06
WO2006036670A1 (en) 2006-04-06
AR050953A1 (en) 2006-12-06
ECSP077360A (en) 2007-04-26
NO20072092L (en) 2007-06-22
US20080132511A1 (en) 2008-06-05
AU2005289887A1 (en) 2006-04-06
MX2007003623A (en) 2007-09-11
US7297816B2 (en) 2007-11-20
US20060069286A1 (en) 2006-03-30
CR9080A (en) 2008-09-09
ZA200702452B (en) 2009-05-27
KR20070057252A (en) 2007-06-04
US20100292240A1 (en) 2010-11-18
CN101061116A (en) 2007-10-24
PE20060823A1 (en) 2006-09-23
EP1797083A1 (en) 2007-06-20
JP2008514608A (en) 2008-05-08
US7855292B2 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
ZA200702452B (en) Sulfonamide compounds
EP1932841A4 (en) Sulfonamide compound
GB0405933D0 (en) Compounds
GB0405937D0 (en) Compounds
EP1755617A4 (en) Perfluorocarbon-soluble compounds
GB0405193D0 (en) Compounds
GB0405272D0 (en) Compounds
GB0405267D0 (en) Compounds
GB0405101D0 (en) Compounds
GB0401269D0 (en) Compounds
GB0408772D0 (en) Compounds
GB0405280D0 (en) Compounds
GB0403593D0 (en) Compounds
GB0405893D0 (en) Compounds
GB0406916D0 (en) Compounds
GB0403595D0 (en) Compounds
GB0401653D0 (en) Compounds
GB0403267D0 (en) Compounds
GB0400697D0 (en) Compounds
GB0405248D0 (en) Compounds
GB0400716D0 (en) Compounds
GB0400695D0 (en) Compounds
GB0403993D0 (en) Compounds
GB0405263D0 (en) Compounds
GB0403998D0 (en) Compounds